News | October 12, 2008

Online Conference Presents Latest Advances in Breast Cancer Patient Care

October 13, 2008 - A nationally recognized faculty will present the very latest treatment strategies for patients with breast cancer in the multimedia course “Optimizing Adjuvant Breast Cancer Strategies: From Biomarkers to Treatment Selection” during National Breast Cancer Awareness Month.

This accredited course offers concise, expert reporting on key, practical treatment innovations, including research from recent American Society of Clinical Oncology (ASCO) annual meetings and San Antonio Breast Cancer Symposia. Highlights of the meeting include:

- Program Chair Antonio C. Wolff, MD, FACP, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will discuss biomarkers

- Harold J. Burstein, M.D., Ph.D., from the Breast Oncology Center, the Dana-Farber Cancer Institute, and Harvard Medical School, will present on recent developments in chemotherapy-biologic treatments.

- Ana Maria Gonzalez-Angulo, M.D., MSc, of The University of Texas M. D. Anderson Cancer Center, will discuss the issue anthracycline related cardiotoxicity

Physicians can register for and take this accredited, virtual e-conference course at any time beginning Tuesday, Oct. 14, 2008, at www.virtualbreastcancer.com. Participants learn at their own pace and utilize interactive case studies, choosing treatments for simulated patients and receiving feedback on their decisions.

The faculty will offer a “Live Question-and-Answer Session” on Oct. 14, 2008, from 12:00-2:00 p.m. (EDT). The course, including faculty presentations and questions and answers generated on Oct. 14, will remain available for one year.
The course is presented by The Johns Hopkins University School of Medicine in cooperation with PharmacoMedia LLC, and is supported by an educational grant from sanofi-aventis U.S. It is available at no cost to participants.

For more information: www.virtualbreastcancer.com

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...